Other
PCSK9 Inhibitor
0
Pipeline Programs↗
7
Active Trials↗
2
Companies Involved↗
PCSK9 Inhibitor is an early-stage landscape with 0 programs across 2 companies. The most active players are Merck & Co., Amgen.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
16
clinical trials
Unknown status4 · 25%
Recruiting4 · 25%
Completed4 · 25%
Not yet recruiting2 · 13%
Active, not recruiting1 · 6%
Terminated1 · 6%
Clinical Trials
Trial Activity
16 trials
PCSK9 Inhibitor for Intracranial Atherosclerotic Symptomatic Stenosis
Not yet recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 3·NCT07119918·5,276 enrolled
INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers
Completed·—·N/A·NCT03273972·30 enrolled
PCSK9 Inhibitor Treatment for Patients With SPG5
Unknown status·FFirst Affiliated Hospital of Fujian Medical University·Phase 1/2·NCT04101643·30 enrolled
Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and Cancer
Unknown status·—·Phase 4·NCT05976893·620 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)